OncLive articleshttps://www.onclive.com/newsOncLive articles© 2026 MJH Life Sciences™ and OncLive. All rights reserved.Wed, 10 Jun 2026 01:17:17 +00005en-us14447https://www.onclive.com/newshttps://www.onclive.com/logo.webphttps://www.onclive.com/view/dr-smith-on-implications-of-data-from-the-frontmind-trial-in-dlbclhttps://www.onclive.com/view/dr-smith-on-implications-of-data-from-the-frontmind-trial-in-dlbcl<![CDATA[Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.]]>Wed, 10 Jun 2026 00:28:13 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-mathews-on-updated-data-from-the-rainfol-01-trial-in-advanced-ovarian-cancerhttps://www.onclive.com/view/dr-mathews-on-updated-data-from-the-rainfol-01-trial-in-advanced-ovarian-cancer<![CDATA[Cara A. Mathews, MD, discusses the updated findings from cohort D2 of the phase 1/2 RAINFOL-01 trial (NCT05579366) in advanced ovarian cancer.]]>Tue, 09 Jun 2026 20:40:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/the-effect-of-obecabtagene-autoleucel-on-adult-patients-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-and-extramedullary-diseasehttps://www.onclive.com/view/the-effect-of-obecabtagene-autoleucel-on-adult-patients-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia-and-extramedullary-disease<![CDATA[Jae Park, MD, discusses findings from the FELIX study showing that obecabtagene autoleucel demonstrated clinically meaningful activity and a manageable safety profile in adults with relapsed/refractory B-cell acute lymphoblastic leukemia, including those with extramedullary disease at lymphodepletion.]]>Tue, 09 Jun 2026 19:12:25 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-flashback-breast-cancer-decisions-and-news-from-may-2026https://www.onclive.com/view/fda-flashback-breast-cancer-decisions-and-news-from-may-2026<![CDATA[Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.]]>Tue, 09 Jun 2026 18:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/ai-powered-atlas-reveals-new-insights-into-tertiary-lymphoid-structures-as-prognostic-and-response-biomarkers-in-cancerhttps://www.onclive.com/view/ai-powered-atlas-reveals-new-insights-into-tertiary-lymphoid-structures-as-prognostic-and-response-biomarkers-in-cancer<![CDATA[New spatial atlas of immune cell structures reveals how key features vary across tumor types and influence patient outcomes.]]>Tue, 09 Jun 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/keynote-d46-trial-is-discontinued-with-sacituzumab-govitecan-plus-pembrolizumab-in-pd-l1-high-nsclchttps://www.onclive.com/view/keynote-d46-trial-is-discontinued-with-sacituzumab-govitecan-plus-pembrolizumab-in-pd-l1-high-nsclc<![CDATA[Lack of a statistically significant PFS improvement and improbability of achieving OS benefit led to the discontinuation of the KEYNOTE-D46/EVOKE-03 trial in PD-L1–high NSCLC.]]>Tue, 09 Jun 2026 15:05:20 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-chen-on-adc-related-toxicity-management-strategies-in-breast-cancerhttps://www.onclive.com/view/dr-chen-on-adc-related-toxicity-management-strategies-in-breast-cancer<![CDATA[Nan Chen, MD, discusses ADC-associated toxicity management in breast cancer, as well as the evolving role of oral SERDs in ER-positive disease.]]>Tue, 09 Jun 2026 14:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/may-s-gi-monthly-rewind-a-landmark-approval-in-cca-expanded-access-for-daraxonrasib-and-more-key-pipeline-updateshttps://www.onclive.com/view/may-s-gi-monthly-rewind-a-landmark-approval-in-cca-expanded-access-for-daraxonrasib-and-more-key-pipeline-updates<![CDATA[Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.]]>Tue, 09 Jun 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/ivonescimab-plus-chemotherapy-versus-tislelizumab-plus-chemotherapy-in-previously-untreated-advanced-squamous-non-small-cell-lung-cancer-overall-survival-results-of-the-phase-3-harmoni-6https://www.onclive.com/view/ivonescimab-plus-chemotherapy-versus-tislelizumab-plus-chemotherapy-in-previously-untreated-advanced-squamous-non-small-cell-lung-cancer-overall-survival-results-of-the-phase-3-harmoni-6<![CDATA[The HARMONi-6 study evaluated ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non–small cell lung cancer. The combination with ivonescimab demonstrated a meaningful overall survival advantage across key patient subgroups while maintaining a manageable and generally comparable safety profile. These findings support ivonescimab plus chemotherapy as a promising new frontline treatment option for this patient population]]>Tue, 09 Jun 2026 12:54:59 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/biomarkers-trials-and-combinations-in-cervical-cancerhttps://www.onclive.com/view/biomarkers-trials-and-combinations-in-cervical-cancer<![CDATA[Clinical management in recurrent cervical cancer increasingly depends on both practical toxicity prevention and thoughtful biomarker assessment. ]]>Tue, 09 Jun 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/gu-cancer-experts-highlight-the-most-impactful-and-discussion-worthy-data-presented-at-asco-2026https://www.onclive.com/view/gu-cancer-experts-highlight-the-most-impactful-and-discussion-worthy-data-presented-at-asco-2026<![CDATA[ASCO 2026 genitourinary experts unpack key prostate and bladder cancer data, revealing practice-changing takeaways and what they mean for patient care.]]>Tue, 09 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/tisotumab-vedotin-in-cervical-cancerhttps://www.onclive.com/view/tisotumab-vedotin-in-cervical-cancer<![CDATA[Tisotumab vedotin is discussed as an important therapeutic step forward for recurrent or metastatic cervical cancer because it offers clinically meaningful activity in a setting where later line treatment has often been disappointing.]]>Tue, 09 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/monotherapy-use-cases-and-future-directions-in-egfr-mutant-nsclchttps://www.onclive.com/view/monotherapy-use-cases-and-future-directions-in-egfr-mutant-nsclc<![CDATA[Learn practical systems for managing EGFR therapy side effects, triage tips, and what’s next for resistance in metastatic NSCLC.]]>Tue, 09 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-singh-on-multidisciplinary-brain-tumor-management-strategieshttps://www.onclive.com/view/dr-singh-on-multidisciplinary-brain-tumor-management-strategies<![CDATA[Raj Singh, MD, highlighted the importance of multidisciplinary collaboration in brain cancer management in observance of World Brain Tumor Day.]]>Mon, 08 Jun 2026 20:20:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/asco-2026-plenary-rasolute-302https://www.onclive.com/view/asco-2026-plenary-rasolute-302<![CDATA[Two Onc Docs provides a review of data from RASolute 302 of daraxonrasib for the second-line treatment of metastatic pancreatic adenocarcinoma.]]>Mon, 08 Jun 2026 19:20:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/subcutaneous-isatuximab-administered-via-obi-approved-in-eu-for-multiple-myelomahttps://www.onclive.com/view/subcutaneous-isatuximab-administered-via-obi-approved-in-eu-for-multiple-myeloma<![CDATA[The EU has approved the use of subcutaneous isatuximab delivered via OBI across all existing indications for IV isatuximab for multiple myeloma.]]>Mon, 08 Jun 2026 17:48:49 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/darovasertib-plus-crizotinib-vs-investigator-s-choice-as-first-line-treatment-for-patients-with-hla-a2-negative-metastatic-uveal-melanoma-primary-results-from-the-optimum-02-trialhttps://www.onclive.com/view/darovasertib-plus-crizotinib-vs-investigator-s-choice-as-first-line-treatment-for-patients-with-hla-a2-negative-metastatic-uveal-melanoma-primary-results-from-the-optimum-02-trial<![CDATA[Marlana Orloff, MD, reviews primary OptimUM-02 data showing darovasertib plus crizotinib significantly improved progression-free survival and response rates versus investigator’s choice in first-line HLA-A2–negative metastatic uveal melanoma, with overall survival data not yet mature.]]>Mon, 08 Jun 2026 17:45:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-leeper-on-meaningful-survivorship-care-for-geriatric-patients-with-brain-cancerhttps://www.onclive.com/view/dr-leeper-on-meaningful-survivorship-care-for-geriatric-patients-with-brain-cancer<![CDATA[Heather Leeper, MD, discussed ideal survivorship care for geriatric patients with brain cancer. ]]>Mon, 08 Jun 2026 17:11:44 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/vopimetostat-plus-daraxonrasib-yields-92-orr-in-mtap-deleted-ras-mutant-pancreatic-cancerhttps://www.onclive.com/view/vopimetostat-plus-daraxonrasib-yields-92-orr-in-mtap-deleted-ras-mutant-pancreatic-cancer<![CDATA[Phase 1/2 data show that the PRMT5 inhibitor vopimetostat plus daraxonrasib yielded a 92% ORR in MTAP-deleted, RAS-mutant metastatic pancreatic cancer.]]>Mon, 08 Jun 2026 16:06:50 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/as-70-of-americans-live-beyond-cancer-city-of-hope-sets-the-standard-for-lifelong-survivorship-carehttps://www.onclive.com/view/as-70-of-americans-live-beyond-cancer-city-of-hope-sets-the-standard-for-lifelong-survivorship-care<![CDATA[City of Hope’s data-driven model integrates survivorship care from diagnosis through decades of follow-up.]]>Mon, 08 Jun 2026 16:06:40 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/independence-type-ii-jak-inhibitor-data-highlight-key-mpn-and-aml-data-arriving-at-eha-2026https://www.onclive.com/view/independence-type-ii-jak-inhibitor-data-highlight-key-mpn-and-aml-data-arriving-at-eha-2026<![CDATA[Experts share the key myeloproliferative neoplasm and acute myeloid leukemia presentations they’re anticipating at the 2026 EHA Congress.]]>Mon, 08 Jun 2026 14:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/romiplostim-significantly-reduces-chemo-dose-delays-modifications-due-to-thrombocytopenia-in-gi-cancershttps://www.onclive.com/view/romiplostim-significantly-reduces-chemo-dose-delays-modifications-due-to-thrombocytopenia-in-gi-cancers<![CDATA[In the phase 3 RECITE trial, romiplostim significantly reduced chemotherapy dose modifications due to thrombocytopenia vs placebo in gastrointestinal cancers.]]>Mon, 08 Jun 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/key-takeaways-from-stellar-303-and-implications-for-treating-mss-metastatic-colorectal-cancerhttps://www.onclive.com/view/key-takeaways-from-stellar-303-and-implications-for-treating-mss-metastatic-colorectal-cancer<![CDATA[Dr. Saeed summarizes the principal clinical lessons from STELLAR 303 and their implications for the management of refractory MSS metastatic colorectal cancer. ]]>Mon, 08 Jun 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/unanswered-questions-and-the-role-of-ctdna-dynamics-in-selecting-intensification-candidates-in-egfr-mutant-nsclchttps://www.onclive.com/view/unanswered-questions-and-the-role-of-ctdna-dynamics-in-selecting-intensification-candidates-in-egfr-mutant-nsclc<![CDATA[In this final episode, Dr. Puri and Dr. Yu close the program with the most important unanswered questions after TOP. The overall survival (OS) data remain immature at roughly 30% maturity, and TOP did not compare osimertinib/chemotherapy head-to-head with amivantamab/lazertinib, so it cannot tell clinicians which intensification regimen is better for the TP53 subgroup. ]]>Mon, 08 Jun 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/stellar-316-trial-design-and-future-directions-for-zanzalintinib-based-therapyhttps://www.onclive.com/view/stellar-316-trial-design-and-future-directions-for-zanzalintinib-based-therapy<![CDATA[Dr. Saeed describes the rationale and design of STELLAR 316, a three-arm phase 3 trial evaluating zanzalintinib-based therapy in patients with stage III MSS colorectal cancer who test positive for circulating tumor DNA following surgery and adjuvant chemotherapy. ]]>Mon, 08 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/unmet-needs-in-plgg-fgfr-altered-tumors-vision-preservation-and-long-term-outcomeshttps://www.onclive.com/view/unmet-needs-in-plgg-fgfr-altered-tumors-vision-preservation-and-long-term-outcomes<![CDATA[Experts spotlight pediatric low-grade glioma gaps: FGFR/KRAS targets, faster safer MEK inhibitors, vision-sparing care, and long-term outcomes.]]>Mon, 08 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/egfr-mutant-nsclc-in-community-settings-practical-guidance-on-first-line-intensification-without-upfront-tp53-statushttps://www.onclive.com/view/egfr-mutant-nsclc-in-community-settings-practical-guidance-on-first-line-intensification-without-upfront-tp53-status<![CDATA[In this episode, Dr. Yu and Dr. Puri offer practical guidance for community oncologists treating newly diagnosed EGFR-mutant metastatic non–small cell lung cancer (NSCLC), where access to rapid TP53 reporting and multidisciplinary supportive care may be limited. ]]>Mon, 08 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/hematologists-highlight-top-data-from-asco-2026https://www.onclive.com/view/hematologists-highlight-top-data-from-asco-2026<![CDATA[Experts highlight some of the top hematologic oncology data presented at ASCO 2026, including key studies in multiple myeloma and diffuse large B-cell lymphoma.]]>Mon, 08 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/aglatimagene-besadenovec-plus-ebrt-improves-prostate-cancer-specific-dfshttps://www.onclive.com/view/aglatimagene-besadenovec-plus-ebrt-improves-prostate-cancer-specific-dfs<![CDATA[Aglatimagene besadenovec plus ERBT displayed an accumulating benefit in high-risk prostate cancer after extended follow-up.]]>Sun, 07 Jun 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-6-1-2026https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-6-1-2026<![CDATA[The top 5 OncLive TV videos of the week cover insights in breast cancer, ovarian cancer, prostate cancer, acute myeloid leukemia, and mantle cell lymphoma.]]>Sun, 07 Jun 2026 12:00:00 GMTOncLiveusOncLive Articles